DexTech Medical

Executive Summary

DexTech Medical is a Swedish private research company founded in 2005, specializing in urological oncology with a primary focus on prostate cancer. The company leverages its proprietary GuaDex carbohydrate-drug-conjugate (CDC) platform to develop targeted small molecule therapeutics. By conjugating drugs to carbohydrates, the platform aims to improve tumor selectivity and reduce systemic toxicity, addressing a significant unmet need in prostate cancer treatment. DexTech operates on a cost-effective model, conducting research through a global collaborative network, and has built a strong clinical foundation through its early-stage pipeline. The company's lead candidate, currently in preclinical development, is designed to target prostate-specific membrane antigen (PSMA) or similar antigens, positioning it as a potential next-generation therapy for hormone-resistant prostate cancer.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 1 clinical trial for lead candidate60% success
• Q3 2026Publication of preclinical efficacy and safety data in a peer-reviewed journal75% success
• 2027Announcement of a strategic partnership or licensing deal for GuaDex platform30% success